AstraZeneca
AZN
768 hedge funds and large institutions have $26B invested in AstraZeneca in 2021 Q2 according to their latest regulatory filings, with 85 funds opening new positions, 266 increasing their positions, 234 reducing their positions, and 63 closing their positions.
43% more call options, than puts
Call options by funds: $681M | Put options by funds: $477M
35% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 63
27% more capital invested
Capital invested by funds: $20.4B → $26B (+$5.57B)
14% more repeat investments, than reductions
Existing positions increased: 266 | Existing positions reduced: 234
2% more funds holding
Funds holding: 755 → 768 (+13)
0.9% more ownership
Funds ownership: 15.63% → 16.53% (+0.9%)
21% less funds holding in top 10
Funds holding in top 10: 14 → 11 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$543M |
| 2 |
Citigroup
New York
|
+$342M |
| 3 |
Goldman Sachs
New York
|
+$283M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$215M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$214M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$309M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$197M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$182M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$158M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$95.9M |
AZN Hedge Fund Activity: Q2 2021 in Review
768 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2021, worth a combined $26B — up 27% from $20.4B a quarter earlier.
Buyers outnumbered sellers: 85 funds opened new AZN positions and 63 closed out — a net gain of 22 holders — while 266 added to existing stakes and 234 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $543M. The largest seller was BlackRock, cutting an estimated $309M.
- 768 institutional investors held AstraZeneca (AZN) as of Q2 2021, up from 755 in Q1 2021.
- Funds reported $26B of AstraZeneca stock for Q2 2021, up 27% quarter-over-quarter.
- 85 funds opened new AstraZeneca positions in Q2 2021 and 63 closed out, a net change of +22 holders.
- The largest AstraZeneca buyer in Q2 2021 was T. Rowe Price Associates, an estimated $543M added.
- The largest AstraZeneca seller in Q2 2021 was BlackRock, an estimated $309M sold.
Based on aggregated 13F filings for Q2 2021.